Oculis Holding AG
OCS
Rank in Stocks
#12309
Oculis Holding AG is a biopharmaceutical company in the clinical development... Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Share Price
$7.76
Last synced: 2026-11-09
Market Cap
$479.04M
Change (1 day)
3.60%
Change (1 year)
-60.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oculis Holding AG (OCS)
Category
Healthcare
Operating Margin for Oculis Holding AG (OCS)
Operating Margin as of November 2026 TTM: -35,874.24%
According to Oculis Holding AG's latest financial reports, its current operating margin (TTM) is -35,874.24%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Oculis Holding AG from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -35,874.24% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -10,671.14% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oculis Holding AG's operating margin
What is Oculis Holding AG's operating margin?
Oculis Holding AG's operating margin is -35,874.24%, as of Nov 2026.
What was Oculis Holding AG's operating margin in 2025?
In 2025, Oculis Holding AG's operating margin was 0.00%, compared with -10,671.14% in 2024.
How has Oculis Holding AG's operating margin changed since 2020?
From 2020 to 2025, Oculis Holding AG's operating margin was highest in 2025 (0.00%) and lowest in 2024 (-10,671.14%).
How does Oculis Holding AG's operating margin compare with similar companies?
Oculis Holding AG's operating margin (-35,874.24%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.